DLBS1033 Therapy in Improving Hypercoagulation State in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 08 Aug 2016
At a glance
- Drugs Lumbricus rubellus (Primary)
- Indications Blood coagulation disorders; Embolism and thrombosis
- Focus Pharmacodynamics
- Sponsors Dexa Medica
- 31 Aug 2018 Biomarkers information updated
- 03 Aug 2016 Status changed from recruiting to completed.
- 25 Nov 2015 Planned End Date changed from 1 Aug 2014 to 1 Oct 2016, according to ClinicalTrials.gov record.